Lead Optimization of Diarylpyrimidines as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase

被引：31
作者：
Zeng, Zhao-Sen [1 ]
Liang, Yong-Hong [1 ]
Feng, Xiao-Qing [1 ]
Chen, Fen-Er [1 ,2 ]
Pannecouque, Christophe [3 ]
Balzarini, Jan [3 ]
De Clercq, Erik [3 ]
机构：
[1] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China
[2] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China
[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
来源：
CHEMMEDCHEM | 2010年 / 5卷 / 06期
基金：
中国国家自然科学基金;
关键词：
HIV-1; inhibitors; NNRTI; reverse transcriptase; structure-activity relationships; POSITIONAL ADAPTABILITY; ANTIVIRAL ACTIVITY; WILD-TYPE; DESIGN; ANALOGS; DRUG; ETRAVIRINE; POTENT; SAR;
D O I：
10.1002/cmdc.201000045
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Antiviral agents: A series of CN-CH2-DAPY analogues were identified as novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-1. Most of the newly synthesized compounds exhibited strong activity against wild-type HIV-1. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.
引用
收藏
页码：837 / 840
页数：4
相关论文
共 17 条
[1]   Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors [J].
Das, K ;
Lewi, PJ ;
Hughes, SH ;
Arnold, E .
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 2005, 88 (02) :209-231
[2]   Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].
Das, K ;
Clark, AD ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Vinkers, HM ;
Daeyaert, F ;
Ludovici, DW ;
Kukla, MJ ;
De Corte, B ;
Kavash, RW ;
Ho, CY ;
Ye, H ;
Lichtenstein, MA ;
Andries, K ;
Pauwels, R ;
de Béthune, MP ;
Boyer, PL ;
Clark, P ;
Hughes, SH ;
Janssen, PAJ ;
Arnold, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560
[3]   The design of drugs for HIV and HCV [J].
De Clercq, Erik .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :1001-1018
[4]   From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125):: Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase [J].
De Corte, BL .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1689-1696
[5]   Structural Modifications of DAPY Analogues with Potent Anti-HIV-1 Activity [J].
Feng, Xiao-Qing ;
Liang, Yong-Hong ;
Zeng, Zhao-Sen ;
Chen, Fen-Er ;
Balzarini, Jan ;
Pannecouque, Christophe ;
De Clercq, Erik .
CHEMMEDCHEM, 2009, 4 (02) :219-224
[6]   Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1 [J].
Guillemont, J ;
Pasquier, E ;
Palandjian, P ;
Vernier, D ;
Gaurrand, S ;
Lewi, PJ ;
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Daeyaert, FFD ;
Vinkers, MH ;
Arnold, E ;
Das, K ;
Pauwels, R ;
Andries, K ;
de Béthune, MP ;
Bettens, E ;
Hertogs, K ;
Wigerinck, P ;
Timmerman, P ;
Janssen, PAJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :2072-2079
[7]   Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity [J].
Heeres, J ;
de Jonge, MR ;
Koymans, LMH ;
Daeyaert, FFD ;
Vinkers, M ;
Van Aken, KJA ;
Arnold, E ;
Das, K ;
Kilonda, A ;
Hoornaert, GJ ;
Compernolle, F ;
Cegla, M ;
Azzam, RA ;
Andries, K ;
de Béthune, MP ;
Azijn, H ;
Pauwels, R ;
Lewi, PJ ;
Janssen, PAJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :1910-1918
[8]  
Heeres J, 2007, ADV ANTIV D, V5, P213, DOI 10.1016/S1075-8593(06)05006-4
[9]  
HO Y, 2004, J MED CHEM, V47, P2550
[10]  
HO Y, 2001, BIOORG MED CHEM LETT, V11, P2229
12